Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer [Phase 1, Phase 2]
A clinical trial update describes a planned first-line treatment for advanced gastric cancer using Fruquintinib in combination with a PD-1 i…
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: A Multicenter Cancer Biospecimen Collection Study
A multicenter cancer biospecimen collection trial sponsored by Cofactor Genomics is currently recruiting, covering multiple cancer indicatio…
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma. [Phase 1]
A Phase 1 trial testing BC001 with Sintilimab and the XELOX regimen for HER-2 negative advanced/metastatic gastric cancer or gastroesophagea…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors [Phase 2]
Phase 2 trial of ladiratuzumab vedotin in multiple advanced solid tumors was terminated, with results posted in March 2025.
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients [Phase 1]
Phase 1 clinical trial evaluating CT041 as postoperative adjuvant therapy for gastric and gastroesophageal junction adenocarcinoma; the stud…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. [Phase 3]
Phase 3 trial update comparing zolbetuximab plus chemotherapy versus placebo plus chemotherapy in adults with gastric and gastroesophageal j…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 [Phase 1]
This Phase 1 study of CMG901 in patients with advanced solid tumors, including gastric cancer and pancreatic cancer, assesses safety, tolera…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. [Phase 1, Phase 2]
Clinical trial update indicating an early-phase study of XNW27011 for multiple advanced solid tumors is currently recruiting.
-
CLINICAL_TRIALS withdrawal · 2025-02-07Clinical Trial Update: Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers [Phase 1]
A Phase 1 neoadjuvant therapy trial for gastroesophageal junction and gastric cancers has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). [Phase 3]
A phase 3 trial (GLOW) evaluating zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN18.2-positive, HER2-negative gastric/GEJ adenocar…
-
FDA approval · 2025-01-27FDA Approved: CYRAMZA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for CYRAMZA (ramucirumab) from Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). [Phase 3]
Phase 3 trial evaluating zolbetuximab plus CAPOX versus placebo plus CAPOX as first-line treatment for CLDN18.2-positive, HER2-negative loca…
-
CLINICAL_TRIALS withdrawal · 2025-01-24Clinical Trial Update: Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 [Phase 1]
The Phase 1 trial of AB-201 for breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-01-22Clinical Trial Update: Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer [Phase 2, Phase 3]
Clinical trial update reporting results from a Phase 2/3 study of tucatinib + trastuzumab + ramucirumab + paclitaxel vs paclitaxel + ramucir…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG [Phase 2]
Phase 2 trial evaluating Fruquintinib plus chemotherapy as postoperative treatment for HER2-negative gastric cancer with poor tumor regressi…
-
CLINICAL_TRIALS approval · 2025-01-09Clinical Trial Update: Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
France granted a temporary authorization for use (ATU) of ramucirumab in combination with paclitaxel for gastric or gastroesophageal junctio…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating tislelizumab plus the SOX regimen (S-1 and oxaliplatin) for locally advanced gastric cancer or gastroesoph…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ [Phase 3]
Phase 3 randomized trial update comparing neoadjuvant treatment strategies for locally advanced, potentially resectable gastroesophageal jun…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy [Phase 2]
A phase 2 clinical trial is evaluating the combination of serplulimab, lenvatinib, and paclitaxel as second-line therapy for advanced gastri…
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ [Phase 2]
Clinical trial update shows sintilimab in combination with chemotherapy with or without local treatment being studied in a Phase 2 trial for…
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors [Phase 1, Phase 2]
BI-1607 in combination with Trastuzumab for HER2-positive advanced solid tumors (Phase 1/2) has been terminated. The study included HER2-pos…
-
CLINICAL_TRIALS research · 2024-12-12Clinical Trial Update: SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]
Phase 3 trial SHR-A1904 vs investigator's choice therapy is recruiting for Claudin18.2-positive second-line advanced or metastatic gastric o…
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: A Study of NDI 1150-101 in Patients With Solid Tumors [Phase 1, Phase 2]
Nimbus Saturn, Inc. is conducting a Phase 1/2 trial of NDI 1150-101 in patients with solid tumors, including renal cell carcinoma, gastric c…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens [Phase 2]
Phase 2 study evaluating trastuzumab deruxtecan monotherapy in HER2-expressing gastric or GEJ adenocarcinoma after two or more prior regimen…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma [Phase 1]
This clinical trial update notes the completion of a Phase 1 pharmacokinetic study of zolbetuximab (IMAB362) in Chinese patients with locall…